Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Total Body Irradiation (TBI) Dose Escalation Decreases Risk of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning for Myelodysplastic Syndrome (MDS) or Myeloproliferative Neoplasms (MPN)

Federico Monaco, MD, Bart L. Scott, MD, Thomas Chauncey, MD PhD, Finn Petersen, MD, Barry E. Storer, PhD, Frederic Baron, Mary E. Flowers, MD, H. Joachim Deeg, MD, Rainer F. Storb, MD, David G. Maloney, MD PhD, Brenda M. Sandmaier, MD

Blood (2017) 130 (Supplement 1): 908.

https://doi.org/10.1182/blood.V130.Suppl_1.908.908

Published: 2017

Journal Articles

Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report

Era L. Pogosova-Agadjanyan, Anna Moseley, Brent L. Wood, MD PhD, Frederick R. Appelbaum, Thomas Chauncey, I-Ming L. Chen, DVM, MS, Harry P. Erba, MD PhD, John E. Godwin, Min Fang, Kenneth J. Kopecky, Alan F. List, Megan Othus, Jerald P. Radich, Cheryl L. Willman, Soheil Meshinchi, Derek L. Stirewalt

Blood (2016) 128 (22): 2890.

https://doi.org/10.1182/blood.V128.22.2890.2890

Published: 2016

Journal Articles

Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial

Brenda M Sandmaier, MD, David G Maloney, MD PhD, Barry E. Storer, PhD, Gitte Olesen, MD, Michael B. Maris, MD, Jonathan A Gutman, MD, Soren Lykke Petersen, MD DMSC, Amelia Langston, MD, Thomas Chauncey, Wolfgang Bethge, MD, Michael A Pulsipher, MD, Brian Thomas Kornblit, MD PhD, Ann E Woolfrey, MD, Marco Mielcarek, MD, Paul J. Martin, MD, Mary E.D. Flowers, MD, Rainer F. Storb, MD

Blood (2016) 128 (22): 506.

https://doi.org/10.1182/blood.V128.22.506.506

Published: 2016

Journal Articles

A Prospective Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil: 10-Year Experience

Huiying Qiu, MD, Brenda M. Sandmaier, MD, Barry E. Storer, PhD, Thomas Chauncey, MD PhD, Finn Petersen, MD, Michael A. Pulsipher, Benedetto Bruno, MD, Mary Flowers, MD, Marco Mielcarek, MD, Rainer Storb, MD, David G Maloney, MD PhD

Blood (2015) 126 (23): 1949.

https://doi.org/10.1182/blood.V126.23.1949.1949

Published: 2015

Journal Articles

Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma

Ryan D. Cassaday, MD, Philip A. Stevenson, MS, Theodore A. Gooley, PhD, Thomas Chauncey, MD PhD, John Pagel, MD PhD, Brian G. Till, MD, Mary Philip, MD PhD, Johnnie J. Orozco, MD PhD, William I. Bensinger, MD, Leona Holmberg, MD PhD, Andrei R. Shustov, MD, Damian J. Green, MD, Stephen D. Smith, MD, Edward N. Libby, MD, David G Maloney, MDPhD, Lorinda A. Soma, MD, Oliver W. Press, MD PhD, Ajay K. Gopal, MD

Blood (2014) 124 (21): 3967.

https://doi.org/10.1182/blood.V124.21.3967.3967

Published: 2014

Journal Articles

Impact Of Pre-Transplant Rituximab Sensitivity In Relapsed Follicular Lymphoma On Outcome After Autologous Transplant

Colin Phipps, MD, Ajay K. Gopal, MD, Barry E. Storer, PhD, Ryan D. Cassaday, MD, Oliver W. Press, MD, PhD, Brian G. Till, MD, John M. Pagel, MD, PhD, Mary Phillip, Maria Corinna Palanca-Wessels, M.D., Ph.D., William I. Bensinger, MD, Leona Holmberg, MD, PhD, Andrei R. Shustov, MD, Damian J. Green, MD, Thomas Chauncey, MD, PhD, David G. Maloney, MD, PhD, Edward N. Libby, III, MD

Blood (2013) 122 (21): 3365.

https://doi.org/10.1182/blood.V122.21.3365.3365

Published: 2013

Journal Articles

Umbilical Cord Blood Transplant Patients At High Risk Of Graft Rejection Achieve Early Full Donor Chimerism When 300cGy Is Used In The Reduced Intensity Conditioning Regimen

Rachel B Salit, MD, Filippo Milano, MD, PhD, Jonathan A Gutman, MD, Michael B Maris, MD, Thomas Chauncey, MD, PhD, Finn Petersen, M.D., Colleen Delaney, MD, MSc

Blood (2013) 122 (21): 697.

https://doi.org/10.1182/blood.V122.21.697.697

Published: 2013

Journal Articles

Specific Features Identify Patients with Relapsed/Refractory Mantle Cell Lymphoma Benefitting From Autologous Hematopoietic Cell Transplantation.

Ryan D. Cassaday, MD, Katherine A. Guthrie, PhD, Lihua E. Budde, MD, PhD, Leslie Thompson, Brian G. Till, MD, Oliver W. Press, MD, PhD, Thomas Chauncey, MD, PhD, John M. Pagel, MD, PhD, Stephen H. Petersdorf, MD, William I. Bensinger, MD, Leona Holmberg, MD, PhD, Andrei R. Shustov, MD, Damian J. Green, MD, Edward N. Libby, III, MD, David G. Maloney, MD, PhD, Ajay K. Gopal, MD

Blood (2012) 120 (21): 3082.

https://doi.org/10.1182/blood.V120.21.3082.3082

Published: 2012

Journal Articles

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose

Merav Bar, MD, Barry Storer, PhD, Benedetto Bruno, MD, Parameswaran Hari, MBBS, MD, MRCP, Thomas Chauncey, MD, PhD, Yoshihiro Inamoto, MD, PhD, Paul J. Martin, MD, Rainer Storb, MD, David G. Maloney, MD, PhD, Brenda M. Sandmaier, MD, Mary E.D. Flowers, MD

Blood (2012) 120 (21): 354.

https://doi.org/10.1182/blood.V120.21.354.354

Published: 2012

Journal Articles

Randomized Comparison of Melphalan 200 Mg/m 2 v. 280 Mg/m 2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

William I. Bensinger, MD, Pamela S Becker, MD, PhD, Ted A. Gooley, PhD, Thomas Chauncey, MD, PhD, David G. Maloney, MD, PhD, Robert Vescio, MD, Ajay K. Gopal, MD, Damian J. Green, MD, Oliver W. Press, MD, PhD, Michael Lill, M.D., Leona Holmberg, MD, PhD, Jainulabdeen J Ifthikharuddin, MD, Gordon L. Phillips, II, MD

Blood (2012) 120 (21): 2009.

https://doi.org/10.1182/blood.V120.21.2009.2009

Published: 2012

Journal Articles

The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation

Frederick L Locke, MD, Joseph Pidala, MD, MS, Barry Storer, PhD, Paul J. Martin, MD, Michael A Pulsipher, MD, Thomas Chauncey, MD, PhD, Niels Jacobsen, MD, DMSC, Nikolaus Kroeger, MD, Irwin Walker, MBBS, Mary C Territo, Susan Light, MD, Ginna G Laport, MD, Auayporn Nademanee, MD, Raymond Powles, MD, Armand Keating, MD, Gerard Socie, MD, Claudio Anasetti, MD

Blood (2012) 120 (21): 4195.

https://doi.org/10.1182/blood.V120.21.4195.4195

Published: 2012

Journal Articles

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts

Boglarka Gyurkocza, M.D., Rainer Storb, MD, Thomas Chauncey, MD, PhD, David G. Maloney, MD, PhD, Barry Storer, PhD, Brenda M. Sandmaier, MD

Blood (2012) 120 (21): 4207.

https://doi.org/10.1182/blood.V120.21.4207.4207

Published: 2012

Journal Articles

The Pre-Transplant Mantle Cell Lymphoma International Prognostic Index Predicts Overall and Progression-Free Survival Following High-Dose Therapy and Autologus Stem Cell Transplant for Mantle Cell Lymphoma

Leslie A Thompson, Katherine A Guthrie, Lihua Elizabeth Budde, MD, PhD, Brian G. Till, MD, Oliver W. Press, MD, PhD, Thomas Chauncey, MD, PhD, John M. Pagel, MD, PhD, Stephen H. Petersdorf, MD, William I Bensinger, MD, Leona Holmberg, MD., PhD, Andrei R. Shustov, MD, Damian J. Green, MD, David G. Maloney, MD, PhD, Ajay K. Gopal, MD

Blood (2011) 118 (21): 2026.

https://doi.org/10.1182/blood.V118.21.2026.2026

Published: 2011

Journal Articles

Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes

Marco Mielcarek, MD, Barry Storer, PhD, Paul J. Martin, MD, Robert S Negrin, MD, Stephen J. Forman, MD, Mary E.D. Flowers, MD, Yoshihiro Inamoto, MD, Thomas Chauncey, MD, PhD, Rainer Storb, MD, Frederick R. Appelbaum, MD, William I Bensinger, MD

Blood (2011) 118 (21): 319.

https://doi.org/10.1182/blood.V118.21.319.319

Published: 2011

Journal Articles

Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data

Laura F Newell, MD, Megan Othus, PhD, Roland B. Walter, MD, PhD, Stephen H. Petersdorf, MD, Thomas Chauncey, MD, PhD, Jeanne E. Anderson, MD, John E. Godwin, MD, MS, Kenneth J. Kopecky, PhD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2011) 118 (21): 1446.

https://doi.org/10.1182/blood.V118.21.1446.1446

Published: 2011

Journal Articles

International Working Group Scores Predict Post-Transplant Outcomes In Patients with Myelofibrosis

Bart Lee Scott, MD, Ted A. Gooley, PhD, Michael L. Linenberger, MD, Brenda M. Sandmaier, MD, David Myerson, MD, Thomas Chauncey, MD, Frederick R. Appelbaum, MD, H. Joachim Deeg, MD

Blood (2010) 116 (21): 3085.

https://doi.org/10.1182/blood.V116.21.3085.3085

Published: 2010

Journal Articles

A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.

Blood (2010) 116 (21): 3450.

https://doi.org/10.1182/blood.V116.21.3450.3450

Published: 2010

Journal Articles

Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors

Blood (2010) 116 (21): 1292.

https://doi.org/10.1182/blood.V116.21.1292.1292

Published: 2010

Journal Articles

Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

Mohamed L. Sorror, MD, MSc, Barry Storer, PhD, Brenda M. Sandmaier, MD, Leanthe Braunert, MD, Ginna G. Laport, MD, Thomas Chauncey, MD, Christopher Bredeson, Richard T Maziarz, MD, Michael A. Pulsipher, MD, Edward Agura, MD, Michael T. Maris, MD, Lars Vindelov, MD, Firoozeh Sahebi, M.D., Peter McSweeney, Benedetto Bruno, MD, Amelia Langston, MD, Rainer F. Storb, MD, David G. Maloney

Blood (2010) 116 (21): 2364.

https://doi.org/10.1182/blood.V116.21.2364.2364

Published: 2010

Journal Articles

Sequential Autologous Followed by Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors Improves Outcomes of Patients (pts) with Bulky Lymphoma or Chronic Lymphocytic Leukemia (CLL)

Mohamed L. Sorror, MD, MSc, Barry Storer, PhD, Brenda M Sandmaier, MD, Thomas Chauncey, MD, Michael T. Maris, MD, Rainer F. Storb, MD, David G. Maloney

Blood (2010) 116 (21): 2365.

https://doi.org/10.1182/blood.V116.21.2365.2365

Published: 2010

NARROW

Total Body Irradiation (TBI) Dose Escalation Decreases Risk of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning for Myelodysplastic Syndrome (MDS) or Myeloproliferative Neoplasms (MPN)

Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report

Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial

A Prospective Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil: 10-Year Experience

Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma

Impact Of Pre-Transplant Rituximab Sensitivity In Relapsed Follicular Lymphoma On Outcome After Autologous Transplant

Umbilical Cord Blood Transplant Patients At High Risk Of Graft Rejection Achieve Early Full Donor Chimerism When 300cGy Is Used In The Reduced Intensity Conditioning Regimen

Specific Features Identify Patients with Relapsed/Refractory Mantle Cell Lymphoma Benefitting From Autologous Hematopoietic Cell Transplantation.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose

Randomized Comparison of Melphalan 200 Mg/m 2 v. 280 Mg/m 2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts

The Pre-Transplant Mantle Cell Lymphoma International Prognostic Index Predicts Overall and Progression-Free Survival Following High-Dose Therapy and Autologus Stem Cell Transplant for Mantle Cell Lymphoma

Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes

Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data

International Working Group Scores Predict Post-Transplant Outcomes In Patients with Myelofibrosis

A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.

Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors

Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

Sequential Autologous Followed by Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors Improves Outcomes of Patients (pts) with Bulky Lymphoma or Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only